Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Traitements Low-Tech pour l'Apnée Obstructive du Sommeil

Thérapie Myofonctionnelle pour l'Apnée Obstructive du Sommeil chez les Membres du Service Américain Avec et Sans Traumatisme Crânien

The overall purpose of this study is to compare changes in sleep outcomes in people with obstructive sleep apnea (OSA) depending on their participation in one of two behavioral interventions; both involve drinking water and breathing. A second purpose is to compare outcomes between people who have sustained a traumatic brain injury (TBI) and those with no history of TBI. The main questions it aims to answer are whether sleep quality improves after 3-months of high-resistance versus low-resistance exercises, and whether people have different outcomes depending on their history of TBI.

Aperçu de l'étude

Description détaillée

Background.

A nonintrusive, inexpensive behavioral approach is emerging as a promising alternative to the management of obstructive sleep apnea (OSA). Generally referred to as myofunctional therapy (MFT), the approach involves exercising the muscles of the oropharynx and respiratory system. The exercises are intended to improve muscle strength and tone so that the muscular structures of the upper airway improve their neuromuscular responsiveness to breathing and resist collapsing into the airway during sleep. They are relatively simple to implement and train, but the regimen requires high-dosage practice and strict dedication to habituate. There is a need for an MFT protocol to be delivered in a consistent manner that is simple, sustainable, and motivating. This study takes advantage of recent low-tech tools that appear to elicit the desired muscle actions achieved with MFT.

Participant Recruitment.

Participants are recruited from the Sleep Clinic at Walter Reed National Military Medical Center if they are suspected to have obstructive sleep apnea, receive a new diagnosis of obstructive sleep apnea (AHI >5) based on standard-of-care polysomnography (PSG), or if they do not successfully use a standard first-line treatment. After providing informed consent and passing screening tests, they are randomized into one of two behavioral interventions.

Interviews will determine whether participants have a history of TBI. Participants in the two intervention arms will be block stratified based on +/- TBI and TBI severity. The groups will also be stratified based on OSA severity.

Interventions.

The interventions involving drinking water through a study-provided water bottle with a specially designed nozzle and breathing in and out through a study-provided handheld breathing device multiple times daily for 3 months. The intervention arms are named for the color of the breathing device. Participants will be informed that the Green option involves exercises intended to relax airway structures and promote better airway patency, and that the Black option involves high-resistance exercises intended to increase airway muscle strength to resist structural collapse. Participants are not informed which of the options is expected to be more therapeutic, but they are informed that both may help and neither will worsen their OSA.

Participants will enter their practice into daily adherence logs, which will be monitored by the study team. A study team member will contact participants every 2 weeks throughout the intervention period to offer encouragement and answer questions.

Assessments.

Pre- and post-intervention measures are obtained from PSG results, self-assessment questionnaires, and measures of tongue and respiratory muscle function. Participants in the experimental group will be given the option to participate in a 3-week follow-up assessment including the questionnaires and muscle-function testing if they are willing to delay first-line treatment for OSA. All participants will be referred back to the Sleep Clinic for standard treatment at the conclusion of the study.

Type d'étude

Interventionnel

Inscription (Estimé)

60

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Maryland
      • Bethesda, Maryland, États-Unis, 20889
        • Recrutement
        • Walter Reed National Military Medical Center
        • Chercheur principal:
          • Nancy P. Solomon, Ph.D.
        • Chercheur principal:
          • Kent Werner, MD, PhD
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Patient with suspected OSA, new diagnosis of OSA (Apnea-hypopnea index, AHI, ≥ 5), or OSA with failure or refusal of first-line treatment;
  • PSG testing within 1 year or planned in the future;
  • Willingness to delay or forego first-line OSA treatment or stop current OSA treatment for 3-4 months;
  • Ability to follow directions and perform the required exercises;
  • At least 18 years of age;
  • DEERS eligible

Exclusion Criteria:

  • Current use of OSA treatment;
  • Medical comorbidities that require restricting fluid intake (e.g., dysphagia, renal disease, liver disease, hyponatremia);
  • Severe nasal obstruction;
  • Severe ankyloglossia;
  • Craniofacial abnormality;
  • Severe pulmonary disease;
  • Severe post-traumatic stress disorder;
  • Very severe insomnia;
  • Body mass index (BMI) ≥35 kg/m2

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Thérapie Myofonctionnelle

Three months of drinking at least 32-oz of water daily through a high-resistance nozzle, and inhaling and exhaling 60 times per day through a high-resistance breathing device

Autres noms:
  • Thérapie Myofonctionnelle Assistée par Dispositif
Comparateur factice: Thérapie de relaxation

Three months of drinking 32-oz of water daily through a low-resistance nozzle, and inhaling and exhaling 40 times per day through a low-resistance breathing device

Autres noms:
  • Thérapie Placebo

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Apnea-Hypopnea Index (AHI)
Délai: From enrollment to end of three-month intervention

AHI is the number of apneic and hypopneic episodes per hour of sleep. The scores start at zero, meaning no events are taking place. A mild score falls in the range of 5-15; moderate 15-30, and a severe diagnosis is 30 or more events per hour. Pre-intervention AHI is obtained from standard-of-care in-clinic sleep study. Post-intervention AHI is obtained from an in-clinic sleep study conducted as part of this research.

From enrollment to end of three-month intervention

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
SpO2
Délai: From enrollment to end of three-month intervention

Oxygen saturation measured during the in-clinic sleep studies. Normal levels range between 95-100%.

From enrollment to end of three-month intervention
Snoring Severity
Délai: From enrollment to end of three-month intervention

Categorized as mild, moderate, or severe.

From enrollment to end of three-month intervention
Epworth Sleepiness Scale (ESS)
Délai: From enrollment to end of three-month intervention with option for additional three-week follow-up

A self-assessment of daytime sleepiness comprising eight questions on a four-point scale (0-3; total range = 0-24). Higher scores indicate greater daytime sleepiness.

From enrollment to end of three-month intervention with option for additional three-week follow-up
Functional Outcomes of Sleep Questionnaire-10 (FOSQ-10)
Délai: From enrollment to end of three-month intervention with option for additional three-week follow-up

A self-assessment of the impact of daytime sleepiness on daily activities. Of the 10 questions, five are rated 0-4 and five are rated 1-4, for a total score ranging between 5-40. A higher score indicates lower impact.

From enrollment to end of three-month intervention with option for additional three-week follow-up

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Tongue Strength
Délai: From enrollment to end of three-month intervention with option for additional three-week follow-up

The maximum pressure generated during tongue-to-palate compression of an air-filled bulb over three trials.

From enrollment to end of three-month intervention with option for additional three-week follow-up
Tongue Endurance
Délai: From enrollment to end of three-month intervention with option for additional three-week follow-up

The maximum duration of sustaining tongue-to-palate compression of an air-filled bulb at 50% of maximum pressure.

From enrollment to end of three-month intervention with option for additional three-week follow-up
Maximal Inspiratory Pressure (MIP)
Délai: From enrollment to end of three-month intervention with option for additional three-week follow-up

The maximum pressures generated during maximal-effort inspiration in cmH2O.

From enrollment to end of three-month intervention with option for additional three-week follow-up
Maximal Expiratory Pressure (MEP)
Délai: From enrollment to end of three-month intervention with option for additional three-week follow-up

The maximum pressures generated during maximal-effort expiration in cmH2O.

From enrollment to end of three-month intervention with option for additional three-week follow-up

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

29 janvier 2026

Achèvement primaire (Estimé)

1 septembre 2027

Achèvement de l'étude (Estimé)

1 décembre 2027

Dates d'inscription aux études

Première soumission

5 novembre 2025

Première soumission répondant aux critères de contrôle qualité

10 décembre 2025

Première publication (Réel)

24 décembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 décembre 2025

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Per a Data Sharing Agreement, de-identified primary and secondary outcome data from Walter Reed National Military Medical Center will be shared with investigators at Uniformed Services University of the Health Sciences, contractors with the Geneva Foundation, and colleagues at University of Minnesota (UMN). UMN colleagues are conducting a concurrent study using the same procedures as the experimental arm; both sites plan to pool data for a larger sample size.

Délai de partage IPD

The study protocol was developed during grant-proposal preparation. Investigators communicate regularly to share updates and coordinate procedures for study implementation. IPD will be made available periodically throughtout data-collection and during data analysis and dissemination (anticipated Jan 2026 -- Dec 2028).

Critères d'accès au partage IPD

The WRNMMC/USUHS research team will share coded data with project-related Geneva Foundation contractors and UMN collaborators.

The coded data will be stored on REDCap, housed on an encrypted password- and firewall-protected server. Authorized project personnel may request IPD through the PIs.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner